WilliamHillÖÐÎĹٷ½ÍøÕ¾

WilliamHillÖÐÎĹٷ½ÍøÕ¾Ò©Òµ¶à°Í°·ÊÜÌ弤¶¯¼Á¿¨Âó½ÇÁÖÆ¬»ñÅúÁÙ´²

ÍþÁ®Ï£¶û¡¤williamhill(Öйú)ÖÐÎĹÙÍø

Ðû²¼Ê±¼ä

2025-08-14

ÍþÁ®Ï£¶û¡¤williamhill(Öйú)ÖÐÎĹÙÍø

ÔĶÁÁ¿

3146

·ÖÏí

ÍþÁ®Ï£¶û¡¤williamhill(Öйú)ÖÐÎĹÙÍø

¿ËÈÕ£¬£¬£¬£¬£¬WilliamHillÖÐÎĹٷ½ÍøÕ¾£¨ÒÔϼò³Æ ¡°WilliamHillÖÐÎĹٷ½ÍøÕ¾Ò©Òµ¡±£©ÊÕµ½¹ú¼ÒÒ©Æ·¼àÊÓ¹ÜÀí¾Ö£¨NMPA£©Åú׼ǩ·¢µÄ¡¶Ò©ÎïÁÙ´²ÊÔÑéÅú׼֪ͨÊé¡·£¬£¬£¬£¬£¬Ô޳ɶà°Í°·D2ÊÜÌ弤¶¯¼ÁGenSci127¿¨Âó½ÇÁÖÆ¬¿ªÕ¹ÁÙ´²ÊÔÑ飬£¬£¬£¬£¬Ä⿪·¢ÓÃÓڸߴßÈéËØÑªÖ¢µÄÖÎÁÆ¡£¡£¡£¡£ ¡£¡£¡£


¸ß´ßÈéËØÑªÖ¢£¨hyperprolactinemia£¬£¬£¬£¬£¬HPRL)


¸ß´ßÈéËØÑªÖ¢ÊÇÓÉÓÚÖÖÖÖÔµ¹ÊÔ­ÓÉÒýÆðÍâÖÜѪÇå´ßÈéËØË®Æ½Ò»Á¬¸ßÓÚÕý³£ÖµµÄÒ»ÖÖÁÙ´²²¡ÀíÐÄÀí״̬£¬£¬£¬£¬£¬ÓɶàÖÖÐÄÀí¡¢Ò©Àí¡¢²¡ÀíÇéÐÎÒýÆð[1]¡£¡£¡£¡£ ¡£¡£¡£Æ¾Ö¤ÏÖÓÐÑо¿£º¸ß´ßÈéËØÑªÖ¢ÄêÇáÅ®ÐÔ³£¼ûµÄÏÂÇðÄÔ-´¹ÌåÖáÄÚÉøÍ¸ÔÓÂÒ£¬£¬£¬£¬£¬25¡«34 Ë긾ٵÄÄê·¢²¡ÂÊΪ23.9/10Íò£»£»£»£»£»£»¼Ì·¢ÐÔ±Õ¾­¼°±Õ¾­ÃÚÈ黼ÕßÖУ¬£¬£¬£¬£¬¸ß´ßÈéËØÑªÖ¢»®·ÖÕ¼ 10%¡«25%¼° 70%¡«80%[1]£»£»£»£»£»£»20%¡«30%¸ß´ßÈéËØÑªÖ¢»¼ÕßÓд¹ÌåÁö£¬£¬£¬£¬£¬×î³£¼ûΪ´ßÈéËØÏÙÁö£¬£¬£¬£¬£¬ÊÇÁÙ´²Éϲ¡ÀíÐԸߴßÈéËØÑªÖ¢×î³£¼ûµÄÔµ¹ÊÔ­ÓÉ¡£¡£¡£¡£ ¡£¡£¡£´ßÈéËØÏÙÁöÒÔ20~50ËêÅ®ÐÔ¶à¼û£¬£¬£¬£¬£¬³ÉÈËÄÐÅ®»¼Õß±ÈÀýԼΪ1:10[1][2]¡£¡£¡£¡£ ¡£¡£¡£


ÏÖÔÚÁÙ´²ÕïÖι²Ê¶Îª£¬£¬£¬£¬£¬¹ØÓڸߴßÈéËØÑªÖ¢¡¢´¹Ìå´ßÈéËØÏÙÁö£¨ÎÞÂÛ΢ÏÙÁö»ò´óÏÙÁö£©£¬£¬£¬£¬£¬¶¼Ê×Ñ¡¶à°Í°·ÊÜÌ弤¶¯¼ÁÖÎÁÆ[2]¡£¡£¡£¡£ ¡£¡£¡ £¿£¿£¿£¿ £¿£¿£¿£¿¨Âó½ÇÁÖÊǾßÓи߶ÈÑ¡ÔñÐԵĶà°Í°·D2ÊÜÌ弤¶¯¼Á£¬£¬£¬£¬£¬ÊDZ»ÍƼöµÄäåÒþͤµÄÌæ»»Ñ¡Ôñ£¬£¬£¬£¬£¬²»Á¼·´Ó¦Ïà¶ÔïÔÌ­£¬£¬£¬£¬£¬×÷ÓÃʱ¼ä¸ü³¤¡£¡£¡£¡£ ¡£¡£¡£Ñо¿Åú×¢¶ÔäåÒþͤ¶Ô¿¹»ò²»ÄÍÊÜäåÒþͤÖÎÁƵϼÕ߸ÄÓÿ¨Âó½ÇÁÖÈÔÓÐ50%ÒÔÉÏÓÐÓÃ[3]¡£¡£¡£¡£ ¡£¡£¡£


¿¨Âó½ÇÁÖÔ­ÑвúÆ·×Ô1992ÄêÆðÔÚÈ«Çò80¶à¸ö¹ú¼Ò»òµØÇø»ñÅúÉÏÊУ¬£¬£¬£¬£¬Îªº£ÄÚÍâÍÆ¼öµÄ¸ß´ßÈéËØÑªÖ¢/´¹Ìå´ßÈéËØÏÙÁöÒ»ÏßÖÎÁÆÒ©Îï[1][2][3]¡£¡£¡£¡£ ¡£¡£¡£ÓÉÓÚº£ÄÚδÉÏÊУ¬£¬£¬£¬£¬»¼ÕßÎÞÕý¹æÍ¾¾¶»ñµÃ£¬£¬£¬£¬£¬±¾´ÎÁÙ´²ÊÔÑéÉêÇë»ñÅúÓÐÍûΪ»¼ÕßÌṩ¸ü¶àµÄÒ©ÎïÑ¡Ôñ¡£¡£¡£¡£ ¡£¡£¡£



²Î¿¼ÎÄÏ×£º

[1] ÖлªÒ½Ñ§»á¸¾²ú¿ÆÑ§·Ö»áÄÚÉøÍ¸Ñ§×é. Å®ÐԸߴßÈéËØÑªÖ¢ÕïÖι²Ê¶. Öлª¸¾²ú¿ÆÔÓÖ¾. 2016;51(3): 161-8.

[2] Öйú´¹ÌåÏÙÁöЭ×÷×é. Öйú´¹Ìå´ßÈéËØÏÙÁöÕïÖι²Ê¶£¨2014°æ£©. ÖлªÒ½Ñ§ÔÓÖ¾. 2014;94(31): 2406-11.

[3] M. Shlomo, F. C. Felipe, R. H. Andrew, L. K. David, M. M. Victor, A. S. Janet, et al. Diagnosis and Treatment of Hyperprolactinemia: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab, February 2011, 96(2): 273-88.


ÉùÃ÷

1.ʵÖÊÁÏÖ¼ÔÚת´ïÇ°ÑØÐÅÏ¢ºÍÖª×ãÒ½ÁÆÎÀÉúרҵÈËÊ¿µÄҽѧÐÅÏ¢ÐèÒª£¬£¬£¬£¬£¬ÎÞÒâÏòÄú×öÈκβúÆ·µÄÍÆ¹ã£¬£¬£¬£¬£¬²»×÷ΪÁÙ´²ÓÃÒ©Ö¸µ¼¡£¡£¡£¡£ ¡£¡£¡£

2.ÈôÄúÏëÏàʶÏêϸ¼²²¡ÕïÁÆÐÅÏ¢£¬£¬£¬£¬£¬Çë×ñ´ÓÒ½ÁÆÎÀÉúרҵÈËÊ¿µÄÒâ¼ûÓëÖ¸µ¼¡£¡£¡£¡£ ¡£¡£¡£

ÍøÕ¾µØÍ¼